Epilepsy Trial, Recruiting (NCT03268824)

Epilepsy Trial, Recruiting NCT03268824 Sponsor: Fondation Ophtalmologique Adolphe de Rothschild Condition: Epilepsy

Printed from Voxsanity (voxsanity.com.au) — NCT03268824 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Epilepsy

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

People who have focal epilepsy that has not been controlled by medication (for the main participant group)
People who do not have drug-resistant focal epilepsy (for the comparison/control group)

Who may not be able to join:

People with severe intellectual disability (an IQ below 50)
People who do not speak French
People for whom an MRI scan is not safe or suitable (for example, those with certain metal implants — confirm with trial site)
People whose epilepsy affects both sides of the brain or multiple brain regions (applies to the main participant group)
People with a condition present from birth that affects how different parts of the brain connect to each other (applies to the control group)
People with lesions or structural damage in the brain tissue (applies to the control group)
People with full or partial blindness in one or both eyes (applies to the control group)
People with full or partial deafness in one or both ears (applies to the control group)
People with an autism spectrum disorder (applies to the control group)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 23 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Vera Dinkelacker, MD PhD, Fondation Ophtalmologique A. de Rothschild

Phone: 0148036431

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT03268824

Sponsor: Fondation Ophtalmologique Adolphe de Rothschild

Phase: Not Applicable

Status: Recruiting

Condition: Epilepsy

Trial contact: 0148036431

More information: https://clinicaltrials.gov/study/NCT03268824

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

People who have focal epilepsy that has not been controlled by medication (for the main participant group)
People who do not have drug-resistant focal epilepsy (for the comparison/control group)

Who may not be able to join:

People with severe intellectual disability (an IQ below 50)
People who do not speak French
People for whom an MRI scan is not safe or suitable (for example, those with certain metal implants — confirm with trial site)
People whose epilepsy affects both sides of the brain or multiple brain regions (applies to the main participant group)
People with a condition present from birth that affects how different parts of the brain connect to each other (applies to the control group)
People with lesions or structural damage in the brain tissue (applies to the control group)
People with full or partial blindness in one or both eyes (applies to the control group)
People with full or partial deafness in one or both ears (applies to the control group)
People with an autism spectrum disorder (applies to the control group)

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 23 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

Fondation Ophtalmologique Adolphe de Rothschild

Registry

ClinicalTrials.gov

Start date

19 December 2017

Est. completion

1 June 2026

Where this trial is recruiting

🇫🇷 France

Primary endpoints

Correlation between the number of cerebral disconnections and the epileptogenicity index

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov